Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail
-

Vyvanse (lisdexamfetamine dimesylate) Capsules

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

 

September 2011

Summary View

ADVERSE REACTIONS

Postmarketing Reports
  • Psychiatric Disorder: dermatillomania

 

November 2010

Summary View

PRECAUTIONS

Drug Interactions
Agents Whose Blood Levels May be Impacted by Vyvanse
  • Extended release guanfacine: In a drug interaction study (N=40), administration of an extended release guanfacine (4 mg) in combination with Vyvanse (50mg) increased guanfacine maximum plasma concentration=by 19%, whereas, exposure (area under the curve; AUC) was increased by 7%. These small changes are not expected to be clinically meaningful. In this study, no effect on d-amphetamine exposure was observed following co-administration of extended release guanfacine and Vyvanse.


ADVERSE REACTIONS

Postmarketing Reports
Immune System Disorders: anaphylactic reaction
 

 

-
-